MedTrace Logo

Impact of Mirabegron on Erectile Function in BPH Patients

NCT04503850 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2020-08-10

No results posted yet for this study

Summary

Evaluation of impact of Mirabegron on erectile function for patients treated for BPH

Conditions

  • Males With Benign Prostatic Hyperplasia Symptoms

Interventions

DRUG

Mirabegron 50 MG

Mirabegron 50 mg daily dose and follow Up of erectile function using international index of erectile function 5 scoring system

DRUG

Alpha Blockers

Alpha blocker daily and evaluation of erectile function using international index of erectile function 5 scoring system

Sponsors & Collaborators

  • Kasr El Aini Hospital

    lead OTHER

Eligibility

Min Age
50 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-01
Primary Completion
2021-05-01
Completion
2021-10-01
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04503850 on ClinicalTrials.gov